Pfizer, Inc. (NYSE:PFE) has been given a $36.00 target price by analysts at Goldman Sachs Group, Inc. (The) in a report issued on Wednesday, November 1st. The brokerage currently has a “neutral” rating on the biopharmaceutical company’s stock. Goldman Sachs Group, Inc. (The)’s price objective would indicate a potential upside of 2.33% from the company’s current price.
Several other research analysts have also commented on the stock. UBS AG set a $38.00 price target on shares of Pfizer and gave the company a “buy” rating in a report on Wednesday, November 1st. Berenberg Bank set a $36.00 price objective on shares of Pfizer and gave the company a “neutral” rating in a research report on Tuesday, October 31st. BMO Capital Markets set a $39.00 price objective on shares of Pfizer and gave the company a “buy” rating in a research report on Tuesday, October 31st. Jefferies Group LLC set a $39.00 price target on shares of Pfizer and gave the stock a “neutral” rating in a research report on Thursday, October 26th. Finally, Deutsche Bank AG set a $38.00 price target on shares of Pfizer and gave the stock a “buy” rating in a research report on Wednesday, October 11th. Two research analysts have rated the stock with a sell rating, eight have issued a hold rating and twelve have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and an average target price of $38.48.
Pfizer (PFE) opened at $35.18 on Wednesday. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.06 and a current ratio of 1.34. The firm has a market cap of $209,697.67, a P/E ratio of 14.07, a price-to-earnings-growth ratio of 2.49 and a beta of 1.01. Pfizer has a one year low of $30.51 and a one year high of $36.78.
Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.67 EPS for the quarter, beating the Zacks’ consensus estimate of $0.65 by $0.02. Pfizer had a net margin of 18.69% and a return on equity of 25.67%. The business had revenue of $13.17 billion for the quarter, compared to the consensus estimate of $13.17 billion. During the same quarter last year, the firm posted $0.61 EPS. The business’s revenue for the quarter was up .9% compared to the same quarter last year. equities analysts expect that Pfizer will post 2.59 EPS for the current year.
ILLEGAL ACTIVITY WARNING: “Pfizer, Inc. (NYSE:PFE) PT Set at $36.00 by Goldman Sachs Group, Inc. (The)” was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this news story on another site, it was illegally copied and reposted in violation of international trademark & copyright legislation. The correct version of this news story can be viewed at https://www.dispatchtribunal.com/2017/11/12/pfizer-inc-pfe-given-a-36-00-price-target-by-goldman-sachs-group-inc-the-analysts.html.
In other news, insider Laurie J. Olson sold 8,064 shares of the firm’s stock in a transaction that occurred on Monday, August 21st. The shares were sold at an average price of $32.70, for a total transaction of $263,692.80. Following the completion of the transaction, the insider now directly owns 74,506 shares of the company’s stock, valued at approximately $2,436,346.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Alexander R. Mackenzie sold 7,350 shares of the firm’s stock in a transaction on Thursday, August 31st. The shares were sold at an average price of $34.00, for a total transaction of $249,900.00. Following the completion of the transaction, the insider now directly owns 132,124 shares of the company’s stock, valued at $4,492,216. The disclosure for this sale can be found here. Insiders have sold a total of 374,621 shares of company stock worth $12,796,098 over the last 90 days. Corporate insiders own 0.06% of the company’s stock.
Hedge funds have recently bought and sold shares of the stock. Shine Investment Advisory Services Inc. acquired a new position in Pfizer in the second quarter valued at about $102,000. Mckinley Capital Management LLC Delaware acquired a new position in Pfizer in the second quarter valued at about $103,000. D. Scott Neal Inc. raised its stake in Pfizer by 19.3% in the second quarter. D. Scott Neal Inc. now owns 3,112 shares of the biopharmaceutical company’s stock valued at $105,000 after purchasing an additional 504 shares in the last quarter. Franklin Parlapiano Turner & Welch LLC acquired a new position in Pfizer in the first quarter valued at about $121,000. Finally, Herndon Capital Management LLC acquired a new position in Pfizer in the second quarter valued at about $120,000. 69.10% of the stock is owned by institutional investors and hedge funds.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.